Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5929030 | American Heart Journal | 2012 | 8 Pages |
Abstract
From the COURAGE trial post hoc substudy, the extent of site-defined ischemia did not predict adverse events and did not alter treatment effectiveness. Currently, evidence supports equipoise as to whether the extent and severity of ischemia impact on therapeutic effectiveness.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Leslee J. PhD, William S. MD, David J. MD, Pamela M. PhD, Rory MD, MS, James K. MD, Marcin MD, G.B. John MD, Sean W. MD, Robert A. MD, John A. MD, MPH, William MD, Gilbert MD, Bernard R. MD, Merill MD, John MD, Piotr PhD, Guido PhD, Daniel S. MD,